BritePear›Research›Tirzepatide
Research · GLP-1 Medications
FDA Approved, Mounjaro & Zepbound
FDA approval applies to the branded versions only. Compounded tirzepatide has a limited, specific allowance under FDA rules. Gray market tirzepatide is never FDA approved.

Tirzepatide, Two Pathways, Better Results

The molecule behind Mounjaro and Zepbound, and how targeting two receptors instead of one changed what weight loss medicine could do.

🍐 Pear It Down ,

Tirzepatide is a dual agonist, it activates both the GLP-1 and GIP receptors simultaneously. Clinical trials showed up to 22.5% average body weight loss over 72 weeks. Beat semaglutide head-to-head in SURMOUNT-5. This is the medication that got Cliff to 249.8 lbs.

Not medical advice. Educational content only, not medical advice. Always consult a licensed healthcare provider before starting any medication.
What It Is

A Dual Agonist, One Step Further

Tirzepatide is a dual agonist, it activates two hormone receptors simultaneously rather than one. It targets the same GLP-1 receptor as semaglutide, but adds the GIP receptor as a second pathway. That combination produced meaningfully better weight loss than GLP-1 alone.

FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), both manufactured by Eli Lilly. A direct head-to-head clinical trial against semaglutide, SURMOUNT-5, confirmed tirzepatide's advantage for sustained weight loss.[2]

22.5%Avg. body weight lossSURMOUNT-1 · 15mg
72Weeks of treatmentSURMOUNT-1
96%Achieved 5%+ weight lossSURMOUNT-1 · 15mg
Cliff's Note

We found tirzepatide the hard way, in a Portuguese pharmacy during a trip in March 2025, after a year without any GLP-1 coverage. The results came back fast. I hit a new all-time low. The difference between semaglutide and tirzepatide was real and noticeable. Not dramatically different day to day, but the trajectory was steeper and more consistent. If you've plateaued on semaglutide, tirzepatide is absolutely worth understanding.

Sources & Citations

  1. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 387:205–216.
  2. Aronne L, et al. (2025). Tirzepatide as Compared with Semaglutide (SURMOUNT-5). N Engl J Med.